Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Haug

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Military Medicine|April 22, 2022
Evaluation of Prescribing Patterns Following Surgical Procedures in Opioid Naïve Patients at a Veterans Affairs Teaching HospitalCaleb Chitwood, Karlie L Haug, Cody Wenthur, et al.
Nucleic Acids Research|February 11, 1987
A monoclonal antibody to triplex DNA binds to eucaryotic chromosomesJ S Lee, G D Burkholder, L J Latimer, et al.
Gene|October 30, 1989
Triplex DNA in plasmids and chromosomesJ S Lee, L J Latimer, B L Haug, et al.
Nucleic Acids Research|May 26, 1987
The alternating conformation of analogues of poly[d(AT)]R S Reid, A L Stuart, S V Gupta, et al.
Leukemia|August 26, 2006
Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myelomaM M Timm, T K Kimlinger, J L Haug, et al.
The British Journal of Dermatology|November 28, 2019
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit diseaseJ Weber, V Glutsch, E Geissinger, et al.
Leukemia|April 27, 2007
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cellsM P Kline, S V Rajkumar, M M Timm, et al.
Experimental Hematology|March 19, 2008
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cellsMichael P Kline, S Vincent Rajkumar, Michael M Timm, et al.
Oncogene|November 26, 2009
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsV Ramakrishnan, M Timm, J L Haug, et al.
American Journal of Hematology|December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycinVijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Military Medicine|April 22, 2022
Evaluation of Prescribing Patterns Following Surgical Procedures in Opioid Naïve Patients at a Veterans Affairs Teaching HospitalCaleb Chitwood, Karlie L Haug, Cody Wenthur, et al.
Nucleic Acids Research|February 11, 1987
A monoclonal antibody to triplex DNA binds to eucaryotic chromosomesJ S Lee, G D Burkholder, L J Latimer, et al.
Gene|October 30, 1989
Triplex DNA in plasmids and chromosomesJ S Lee, L J Latimer, B L Haug, et al.
Nucleic Acids Research|May 26, 1987
The alternating conformation of analogues of poly[d(AT)]R S Reid, A L Stuart, S V Gupta, et al.
Leukemia|August 26, 2006
Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myelomaM M Timm, T K Kimlinger, J L Haug, et al.
The British Journal of Dermatology|November 28, 2019
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit diseaseJ Weber, V Glutsch, E Geissinger, et al.
Leukemia|April 27, 2007
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cellsM P Kline, S V Rajkumar, M M Timm, et al.
Experimental Hematology|March 19, 2008
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cellsMichael P Kline, S Vincent Rajkumar, Michael M Timm, et al.
Oncogene|November 26, 2009
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsV Ramakrishnan, M Timm, J L Haug, et al.
American Journal of Hematology|December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycinVijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
Pageof 3